Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05559359 · ClinicalTrials.gov registry record · Phase 3
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
A Phase 3 study of Atopic Dermatitis and Eczema, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 367
- Enrollment target
- 20
- Study locations
NCT05559359: Active Phase 3 study of Atopic Dermatitis and Eczema, sponsored by Eli Lilly and Company.
NCT05559359 is a Phase 3 study of Atopic Dermatitis and Eczema that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 367 participants, below the 607-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (40% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05559359, a Phase 3 study of Atopic Dermatitis and Eczema, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 367 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18 years of age with moderate-to-severe atopic dermatitis (AD).
Primary Outcome
EASI-75 is a co-primary endpoint with IGA.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Lebrikizumab
- DRUG Topical Corticosteroid (TCS)
Study Locations (20)
California
- First OC Dermatology - Fountain Valley
- Antelope Valley Clinical Trials - Lancaster
- Dermatology Research Associates - Los Angeles
- Integrative Skin Science and Research - Sacramento
- Rady's Children Hospital San Diego - Dermatology - San Diego
Florida
- Solutions Through Advanced Research - Jacksonville
- ForCare Clinical Research - Tampa
Alabama
- Clinical Research Center of Alabama - Birmingham
Arizona
- Phoenix Children's Hospital - Phoenix
Arkansas
- Arkansas Research Trials - North Little Rock
Connecticut
- UConn Health - Farmington
Idaho
- Treasure Valley Medical Research - Boise
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 367 participants |
| Start Date | 2022-10-18 |
| Est. Completion | 2026-12 |
| Phase | Phase 3 |
What the registry record for NCT05559359 still lists
NCT05559359 is an interventional study that assigns participants to a tested intervention. The registered 367 participants enrollment target is mid-sized for trials with a published cap, below the 607-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (40% lower).
The record links to 2 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05559359 names 20 study sites across 15 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT05559359 about?
NCT05559359 is a clinical study titled "A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis". The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18 years of age with moderate-to-severe atopic dermatitis (AD).
What is the current status of trial NCT05559359?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 367 participants. The study started on 2022-10-18. Estimated completion is 2026-12.
What conditions does trial NCT05559359 study?
This clinical trial studies the following conditions: Atopic Dermatitis, Eczema.
What interventions are being tested in trial NCT05559359?
The interventions under investigation include: Placebo (DRUG), Lebrikizumab (DRUG), Topical Corticosteroid (TCS) (DRUG).
Who is sponsoring clinical trial NCT05559359?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05559359 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05559359's enrollment target sits among peer trials
367 37th of 150 higher than 114 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
RECRUITING · Phase 3
-
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
RECRUITING · Phase 3
-
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
RECRUITING · Phase 3
-
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04675476 · 368 participants · NA
A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening
- NCT05215353 · 368 participants · Phase 4
A Study Comparing Music Therapy and Cognitive Behavioral Therapy for Anxiety in Cancer Survivors
- NCT06182397 · 368 participants · NA
Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease
- NCT06629610 · 368 participants · NA
Diet and Active Lifestyle - Yuuyaraq (The Yup'ik Way of Life)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI